期刊
CELLULAR AND MOLECULAR LIFE SCIENCES
卷 71, 期 22, 页码 4325-4346出版社
SPRINGER BASEL AG
DOI: 10.1007/s00018-014-1677-1
关键词
mTOR; Mammalian target of rapamycin; Longevity; Lifespan; Aging; Rapamycin; Mice; Mammals; Disease; Treatment; Drug; Prevention; Mechanism; Neurodegeneration; Cardiovascular disease; Cancer; Anti-aging
The federal drug administration (FDA)-approved compound rapamycin was the first pharmacological agent shown to extend maximal lifespan in both genders in a mammalian species. A major question then is whether the drug slows mammalian aging or if it has isolated effects on longevity by suppressing cancers, the main cause of death in many mouse strains. Here, we review what is currently known about the effects that pharmacological or genetic mammalian target of rapamycin (mTOR) inhibition have on mammalian aging and longevity. Currently available evidence seems to best fit a model, wherein rapamycin extends lifespan by suppressing cancers. In addition the drug has symptomatic effects on some aging traits, such as age-related cognitive impairments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据